The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis.

Leonardo ProvenzanoRiccardo LobefaroFrancesca LigorioEmma ZattarinLuca ZambelliCaterina SposettiDaniele PrestiGiulia MontelaticiAngela FicchìAntonia MartinettiAlessio ArataMarta Del VecchioClaudia Lauria PantanoBarbara FormisanoGiulia Valeria BianchiGiuseppe CapriFilippo de BraudClaudio VernieriGiovanni Fucà

Published in: Therapeutic advances in medical oncology (2023)

PIV has a promising prognostic discrimination ability in aTNBC patients treated with first-line, platinum-based chemotherapy. Both baseline and early on-treatment PIV are associated with clinical outcomes and may be exploited for creating PIV-based risk classifiers if further validated.

Keyphrases

locally advanced
oxidative stress
squamous cell carcinoma
combination therapy
rectal cancer
replacement therapy
newly diagnosed
smoking cessation